Project Grant R01CA298313
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $702K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This $738,698 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Beckman Research Institute of the City of Hope supports research on a novel anti-CD38 targeted alpha therapy (TAT) combined with total marrow irradiation (TMLI) for the treatment of relapsed/refractory acute myelogenous leukemia (AML) in patients over 60 years old. The goal is to develop an innovative, organ-sparing radiotherapy approach that can safely escalate the radiation...
- The National Cancer Institute (NCI) awarded a $1,477,396 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope in Duarte, CA. The grant, awarded on December 1, 2024, supports a novel approach to enhance the efficacy and durability of CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin's lymphoma (B-NHL). The project involves selecting cytomegalovirus (CMV)-specific T cells, modifying them with a...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $457,683 to the Beckman Research Institute of the City of Hope to develop and evaluate novel "Bio-Beacons" - tumor-targeting bacterial vectors engineered to secrete chemokines and cytokines. The goal is to increase the density of tumor-reactive immune cells, such as CD8 T cells, CD4 T cells, dendritic cells, and natural killer cells, within solid tumors. This is...
- This federal Project Grant award of $663,340 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to elucidate the mechanisms by which the ablation of intratumoral regulatory T cells can mobilize NK cells and CD4 T cells to control MHC I-deficient tumors. The research aims to determine how CD4 T cell help enhances the antitumor function of NK cells, including the role of cytokines like IL-2 and IL-15, as well as test whether intratumoral Treg depletion...
- This $1,124,607 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports a Phase 2 multi-center clinical trial of a novel CD5 chimeric antigen receptor (CAR) T-cell therapy (MB-105) developed by March Biosciences Inc. for the treatment of relapsed/refractory T-cell lymphoma (R/R TCL). The grant, awarded from July 1, 2025 to June 30, 2027, will validate the safety and efficacy of the improved MB-105 product, which has demonstrated promising results in...
- This Project Grant award of $1,759,998.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the Beckman Research Institute of the City of Hope to potentiate T cell activity against multiple myeloma through inhibition of sumoylation. The research aims to transform healthcare for Service Members and the American public through innovative and impactful work. The award term runs from Aug 1, 2023 to Jul 31, 2026. As a...
- This $549,460 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Florida to study the role of the BCL11B transcription factor in regulating CD8+ T cell response and memory in tumor microenvironments. The award aims to establish the transcriptional programs and epigenomic landscape controlled by BCL11B in mouse T cells, with the goal of understanding...
- This $615,999 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Beckman Research Institute of the City of Hope, a nonprofit organization. The grant funds research to develop a "Targeted Telomere-Disrupting Oligonucleotide for Acute Myeloid Leukemia Therapy" over a 3-year period from Sep 1, 2023 to Aug 31, 2026. As a nonprofit research organization, Beckman Research Institute leverages its medical...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $734,435.00 in funding to the Beckman Research Institute of the City of Hope to conduct research aimed at overcoming resistance to BH3 mimetic drugs in the treatment of acute myeloid leukemia (AML), particularly in older patients. The key objectives are to define the molecular mechanisms underlying BH3 mimetic resistance in AML and evaluate whether targeting the ADSS2 enzyme,...
- This $517,090 federal Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Beckman Research Institute of the City of Hope supports innovative research aimed at understanding the role and function of a novel gene, A978, which is overexpressed in Philadelphia chromosome-positive and Philadelphia-like B-cell acute lymphoblastic leukemia (B-ALL). The key objectives of this 5-year project are to: 1) determine the biological effects of A978 in...